CD8A and neoplasm: Both viral status (MCV-positive or negative) [12] and infiltrating immune cells (e.g., neutrophils and CD8 lymphocytes) [13,14,15] can be pivotal contributors to either a pro- or anti-TME, which in turn may impact the migratory functions of the tumor cells (e.g., assessed by loss of E-cadherin) [16,17,18] and response to immune checkpoint inhibitors (generally enhanced in tumors with PD-L1 expression) [19].